- Takeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appealTakeda has updated its financial results to reflect costs it could incur after losing an antitrust lawsuit concerning its laxative drug Amitiza. In May, the US District Court in Massachusetts rul…Endpoints · 1mo ago↗ source
- Nurix to work with Roche on BTK degrader in pact worth up to $2.3BRoche is set to pay Nurix Therapeutics $700 million upfront to collaborate on a BTK degrader for B cell malignancies, with broader plans in immunology and neurology. The deal could be ...Endpoints · 1mo ago↗ source
- #ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effectsBoehringer Ingelheim’s obesity asset survodutide, which it licensed from Zealand Pharma, has shown high rates of discontinuations in its Phase 3 obesity study. In April, data from the SYNCHRONIZE…